News Release

Journal Article Cites Cleanascite™ To Determine the Role of Fatty Acids in Tumor-Associated Macrophage Polarization in Ovarian Cancer

MONMOUTH JUNCTION, NJ, September 9, 2024 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation from omental conditioned medium (OCM), to in a study of protumoral M2-like macrophages in ovarian cancer. The citation is:

Wang, H., Yung, M.M., Xuan, Y. et al. Polyunsaturated fatty acids promote M2-like TAM deposition via dampening RhoA-YAP1 signaling in the ovarian cancer microenvironment. Exp Hematol Oncol 13, 90 (2024). https://doi.org/10.1186/s40164-024-00558-8

Peritoneal metastases frequently occur in epithelial ovarian cancer (EOC), resulting in poor prognosis and survival rates. Tumor-associated-macrophages (TAMs) massively infiltrate into ascites spheroids and are multi-polarized as protumoral M2-like phenotype. However, the impact of omental conditioned medium/ascites (OCM/AS) on TAM polarization and its function in tumor progression remains elusive. The article states “Recent studies have suggested that lipid accumulation and metabolism are associated with the differentiation and activation of protumoral TAMs. Hence, we examined the lipid droplets (LDs) in MФs, which are cellular storage organelles for neutral lipids. …the removal of free fatty acids in OCM by Cleanascite™ attenuated LDs deposition in OCM-C MФs (macrophages polarized in OCM pretreated with Cleanascite™) (Fig. 4A), indicating M2 MФs and OCM-MФs exhibited higher lipid accumulation and metabolism….Likewise, we demonstrated that the cellular ROS levels in OCM/AS-MΦs derived from PBMC MΦs were significantly upregulated, whereas the addition of Cleanascite™ mitigated the increased ascites-mediated ROS level, indicating that the accumulation of intercellular UFAs is responsible for the enhanced ROS production in OCM-MФs (Fig. 4D.” The article goes on to state “In contrast, removing lipids by Cleanascite™ remarkably prevented the reduction of YAP1 in OCM-MΦs (Fig. 5G).

From Figure 4A

From Figure 5G.

This study revealed that PUFAs-enriched OCM/AS of EOC promotes M2-like TAM polarization through RhoA-YAP1 inhibition, where YAP1 downregulation is required for accelerating protumoral M2-like TAM polarization, thereby causing immunosuppression and enhancing tumor progression.

“We now have over thirty references, showing Cleanascite™ use in helping to identify a characteristic feature of in vitro cell response. Notably, this is the fifth reference that specifically investigated the role of lipids in macrophage polarization in cancer cell lines. Unlike alternative lipid-depletion methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. The essential requirement is the maintenance of cellular activity after lipid depletion, to determine whether lipid factors are associated with phenotypic changes in cultured cells” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Download whitepaper entitled “Cleanascite™ - Lipid Removal and Cell Response Applications”, visit:

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Lipid depletion, lipid metabolism, Cleanascite™, Tumor microenvironment, Immunometabolism, TAM polarization, Ovarian cancer and ascites, Polyunsaturated fatty acids, RhoA-YAP1 signaling

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for targeted proteomics and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com